Montelukast

• Treatments of COVID-19 in primary care in the Netherlands Not authorised
  2022-500678-33-00 Phase IV 1 country Maastricht University
• RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE… Recruiting
  2025-521802-17-00 Phase III 3 countries Farmalider S.A.
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended
  2023-504331-41-00 Phase III 9 countries Sanofi-Aventis Research & Development
• The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endoth… Ended
  2024-511894-32-00 Phase III 1 country Uniwersytet Jagiellonski Collegium Medicum
• A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of … Ended
  2023-506137-30-00 Phase II 1 country Farmalider S.A.
• Randomised, crossover bioequivalence clinical trial of montelukast 10 mg capsules vs montelukast 10 mg film-coated tablets, after a single o… Ended
  2023-506937-30-00 1 country Laboratorios Alter S.A.
• Treatments of COVID-19 in primary care in the Netherlands Ended
  2022-501559-99-00 Phase IV 1 country Maastricht University
• A Phase 2 Study of LTX-315 in Combination with Pembrolizumab in Patients with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy (… Ended
  2022-500628-31-00 Phase II 3 countries Lytix Biopharma AS

Showing 1–9 of 9 trials